PDCD1 and kidney cancer: The use of PD-1 and CTLA-4 checkpoint inhibitors increased patient survival compared with traditional chemotherapy in a number of studies, including studies on kidney cancer, melanoma, head and neck squamous cell cancer (HNSCC) and non-small cell lung cancer [18].